Tag Archives: Martin Landry

GMP FirstEnergy Thinks Emblem Corp’s Stock is Going to Recover

Yesterday, an analyst has provided a rating update for the Healthcare company, Emblem Corp (TSXV: EMC). Analyst Martin Landry from GMP FirstEnergy rated Emblem Corp (TSXV: EMC) a Buy, setting a C$1.75 price target. According to TipRanks.com, Landry is ranked

GMP FirstEnergy Reiterates Their Hold Rating on Aimia Inc.

The Services sector company, Aimia Inc. (TSX: AIM), has received a rating update from a Wall Street analyst yesterday. GMP FirstEnergy’s analyst Martin Landry reiterates their Hold rating on the shares, with a C$4 price target. According to TipRanks.com, Landry

Cipher Pharma Gets a Buy Rating from GMP FirstEnergy

Wall Street analyst has provided a review for the Healthcare company today, but retained the same rating on the stock. GMP FirstEnergy’s analyst Martin Landry reiterates their Buy rating on the shares of Cipher Pharma (TSX: CPH), with a C$7

GMP FirstEnergy Reiterates a Buy Rating on Knight Therapeutics

Knight Therapeutics (TSX: GUD), the Healthcare company was revisited today, and remains undervalued for at least one analyst on the street. Analyst Martin Landry from GMP FirstEnergy reiterated a Buy rating, with a C$10 price target. According to TipRanks.com, Landry

GMP FirstEnergy Thinks Cipher Pharma’s Stock is Going to Recover

In a new note to investors today, an analyst has provided a rating update for the Healthcare company, Cipher Pharma (TSX: CPH). Analyst Martin Landry from GMP FirstEnergy remains bullish on the stock and has a C$8 price target. According

GMP FirstEnergy Sticks to Its Hold Rating for Aimia Inc.

Wall Street analyst has provided a review for the Services company today, but retained the same rating on the stock. Analyst Martin Landry from GMP FirstEnergy rated Aimia Inc. (TSX: AIM) a Hold, setting a C$2.75 price target. According to